SCHEMBL1029034

SCHEMBL1029034

COc1ccc(C(=O)O)cc1OCc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.75
HDAC1 Q13547 1/20 0.75
HDAC8 Q9BY41 1/20 0.75
HDAC6 Q9UBN7 1/20 0.75
RXRA P19793 1/20 0.73
MRGPRX4 Q96LA9 4/20 0.72
NPC1 O15118 1/20 0.68
HPGD P15428 1/20 0.68
RAB9A P51151 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
CA4 P22748 1/20 0.65
CA6 P23280 1/20 0.65
CA7 P43166 1/20 0.65
TPMT P51580 1/20 0.65
CA9 Q16790 1/20 0.65
CA14 Q9ULX7 1/20 0.65
PDE4A P27815 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375753 1.00 SMPD1 (0.75) SMPD1HDAC1HDAC8HDAC6RXRA
Hydrochloric Acid SCHEMBL6586504 0.98 SMPD1 (0.73) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL11271923 0.98 SMPD1 (0.73) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL242563 0.94 MRGPRX4 (0.77) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL11277266 0.93 MRGPRX4 (0.75) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL29556736 0.91 MRGPRX4 (0.62) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL1600077 0.91 MRGPRX4 (0.62) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL4270566 0.90 SMPD1 (0.73) SMPD1HDAC1HDAC8HDAC6RXRA
SCHEMBL9236564 0.90 SMPD1 (0.73) SMPD1HDAC1HDAC8HDAC6RXRA
Hydrochloric Acid SCHEMBL10857748 0.89 MRGPRX4 (0.61) SMPD1HDAC1HDAC8HDAC6RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103980152-B Benzamide compounds with anti-tumor activity and its preparation method and application XI'AN JIAOTONG UNIVERSITY (CN) 2016-04-27 CN claimed
CN-103980152-A Benzamide compound with antitumor activity as well as preparation method and application thereof UNIV XI AN JIAOTONG 2014-08-13 CN claimed
EP-2279732-A2 Compounds and compositions for delivering active agents Emisphere Technologies, Inc. (US) 2011-02-02 EP claimed
CN-1964939-A Compounds and compositions for delivering active agents EMISPHERE TECH INC (US) 2007-05-16 CN claimed
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
EP-4678637-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS A-chembio Co., Ltd (KR) 2026-01-14 EP disclosed
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS A-CHEMBIO CO., LTD (KR) 2024-09-12 US disclosed
WO-2024186175-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS 주식회사 에이켐바이오 2024-09-12 WO disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
CN-110305072-B Compounds with phosphodiesterase 4D and acid sphingomyelinase inhibitory activity and uses thereof 中国药科大学 2023-09-19 CN disclosed
US-20230115176-A1 Complement Modulators and Related Methods RA PHARMACEUTICALS, INC. 2023-04-13 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
EP-0865439-A4 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS INC (US) 1998-11-11 EP disclosed
EP-0865439-A1 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS, INC. (US) 1998-09-23 EP disclosed
US-5629340-A DIPHENYL FURAN COMPOUNDS TSUMURA & CO. (JP) 1997-05-13 US disclosed
WO-1996040672-A1 COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS ISIS PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
EP-0678296-A1 VASCULARIZATION INHIBITOR AND NOVEL COMPOUND TSUMURA & CO. (JP) 1995-10-25 EP disclosed
EP-0613879-A1 PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT TSUMURA & CO. (JP) 1994-09-07 EP disclosed
EP-0019081-B1 FLAVONE DERIVATIVES, THEIR PREPARATION, THESE NOVEL AND KNOWN FLAVONES AS ANTIVIRAL AGENTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-10-24 EP disclosed
EP-0019081-A1 Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115176-A1 Complement Modulators and Related Methods C5, C9, C1QBP SMPD1 300/4885HDAC1 2943/4885HDAC8 3160/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A SMPD1 126/4885HDAC1 171/4885HDAC8 1129/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B SMPD1 197/4885HDAC1 1106/4885HDAC8 1054/4885
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS HGF, FN1, SMAD2 SMPD1 3606/4885HDAC1 2640/4885HDAC8 1650/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A SMPD1 119/4885HDAC1 210/4885HDAC8 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.